Nanobiotix (NASDAQ:NBTX) Coverage Initiated at Guggenheim

Guggenheim started coverage on shares of Nanobiotix (NASDAQ:NBTX) in a research report issued to clients and investors on Wednesday, Benzinga reports. The firm set a “buy” rating and a $12.00 price target on the stock. Guggenheim’s price objective would indicate a potential upside of 133.92% from the company’s current price.

Nanobiotix Stock Performance

Nanobiotix stock opened at $5.13 on Wednesday. The business has a 50-day moving average of $5.13 and a 200-day moving average of $5.93. Nanobiotix has a 1 year low of $4.14 and a 1 year high of $10.70.

Nanobiotix Company Profile

Nanobiotix SA, a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer.